{"product_id":"xerispharma-swot-analysis","title":"Xeris SWOT Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMake Insightful Decisions Backed by Expert Research\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eXeris faces promising niche opportunities in specialty endocrinology and innovative delivery tech but must navigate regulatory timing, reimbursement uncertainty, and commercial scale challenges; our full SWOT unpacks these elements with financial context and tactical recommendations. Purchase the complete analysis to receive an investor-ready Word report and editable Excel matrix for strategy, due diligence, or pitch use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etrengths\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProprietary Formulation Technology Platforms\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eXeris’ XeriSol and XeriJect platforms enable highly concentrated, stable, ready-to-use injectable drugs that skip complex reconstitution, creating a clear product moat; their tech supports subcutaneous or intramuscular delivery of biologics and small molecules, reducing clinic time and supply-chain costs. In 2025 Xeris reported XeriSol-based products cut cold-chain logistics by ~30% and improved adherence rates in trials by 12–18%, boosting per-patient economics and prescriber preference.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDiversified Commercial Product Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cpas of late xeris generates diversified revenue from three commercial products keveyis paralysis and recorlev together produced roughly million in net product sales fy sustained sequential growth into\u003e\n\u003c\/pas\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eScalable Manufacturing and Operational Efficiency\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cpxeris has optimized manufacturing for liquid-stable formulations that largely avoid cold-chain logistics cutting distribution costs and complexity in this supported a gross margin above many biotech peers. the streamlined ops raise throughput reduce per-unit cost so adding new pipeline candidates uses existing lines with minimal capex. incremental revenue scales at higher helping sustain ebitda improvement as sales grow.\u003e\n\u003c\/pxeris\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Partnerships and Licensing Revenue\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eXeris has partnered with Regeneron and Horizon Therapeutics to apply its XeriJect formulation to large-molecule assets, attracting non-dilutive funding via upfronts, milestones, and royalties that bolstered cash runway—2024 licensing receipts exceeded $25M including a $12M upfront from Horizon in Sept 2024.\u003c\/p\u003e\n\u003cp\u003eEndorsements from top pharma validate XeriJect’s technical efficacy and reduce development risk, supporting revenue diversification and balance-sheet stability as of Q4 2024.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 licensing revenue \u0026gt;$25M\u003c\/li\u003e\n\u003cli\u003e$12M Horizon upfront (Sep 2024)\u003c\/li\u003e\n\u003cli\u003eRegeneron collaboration for large molecules\u003c\/li\u003e\n\u003cli\u003eNon-dilutive funding: upfronts, milestones, royalties\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrong Intellectual Property Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eXeris Pharma holds patents covering formulation science and ready-to-use delivery mechanisms that extend into the mid-to-late 2030s, shielding its subcutaneous and liquid-stable platforms from easy replication.\u003c\/p\u003e\n\u003cp\u003eThis legal moat helps protect revenue streams—Gvoke sales and other partnered royalties—by limiting generic entrants and boosting negotiation leverage for licensing or M\u0026amp;A, directly supporting long-term valuation.\u003c\/p\u003e\n\u003cp\u003eHere’s the quick math: patent life to 2035+ preserves pricing power for a decade; stronger IP typically raises acquisition multiples by 10–30% in biotech deals.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePatents through mid\/late 2030s\u003c\/li\u003e\n\u003cli\u003eProtects ready-to-use formats\u003c\/li\u003e\n\u003cli\u003eSupports royalties and Gvoke revenue\u003c\/li\u003e\n\u003cli\u003eBoosts M\u0026amp;A\/licensing leverage\u003c\/li\u003e\n\u003cli\u003eMay add ~10–30% to acquisition multiples\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eXeris’ XeriSol\/Ject: $175M sales, 30% less cold‑chain, 12–18% adherence lift, patents into 2030s\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eXeris’ XeriSol\/XeriJect enable ready-to-use, liquid-stable injectables, cutting cold-chain needs ~30% and raising adherence 12–18% (2025); FY2024 product sales ≈ $175M with licensing receipts \u0026gt;$25M (2024). Patents into mid\/late 2030s protect pricing and boost M\u0026amp;A leverage.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eFY2024 sales\u003c\/td\u003e\n\u003ctd\u003e$175M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2024 licensing\u003c\/td\u003e\n\u003ctd\u003e$25M+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCold-chain reduction\u003c\/td\u003e\n\u003ctd\u003e~30%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdherence lift\u003c\/td\u003e\n\u003ctd\u003e12–18%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatent life\u003c\/td\u003e\n\u003ctd\u003emid\/late 2030s\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eProvides a clear SWOT framework for analyzing Xeris’s business strategy, highlighting internal capabilities, market strengths, operational gaps, growth drivers, and external risks shaping its competitive position.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eDelivers a concise SWOT snapshot of Xeris for rapid strategy alignment and stakeholder briefings, simplifying decision-making and cross-team communication.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eW\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eeaknesses\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConcentrated Customer Base and Payor Risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cpa significant share of xeris healthcare plc revenue product sales from a handful specialty distributors and two major pharmacy benefit managers creating clear concentration risk. changes in pbm reimbursement or formulary placement can cut net quickly saw quarterly swing after change. maintaining pricing power is hard the us: cms commercial payors pressure u.s. drug prices while inflation rebate demands compress margins.\u003e\n\u003c\/pa\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh Debt Service Obligations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDespite revenue growth to $226.6M in 2024, Xeris Therapeutics (XERS) carried about $160M of long-term debt as of Q4 2024; annual interest expense of roughly $12–15M cuts free cash flow and constrains funding for R\u0026amp;D or new M\u0026amp;A.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHeavy Reliance on Specialty Markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cpxeris portfolio focuses on niche rare-disease drugs like keveyis paralysis and recorlev syndrome capping total addressable market sizes covers us patients top-line scalability is constrained.\u003e\n\u003cpmaintaining share requires a specialized high-cost sales force xeris reported million commercial sg in reflecting that expense burden.\u003e\n\u003cpwhile per-patient margins are strong the company must work harder to find and convert a limited patient pool raising customer-acquisition cost concentration risk.\u003e\n\u003c\/pwhile\u003e\u003c\/pmaintaining\u003e\u003c\/pxeris\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHistorical Lack of Consistent Net Profitability\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eXeris moved toward cash-flow breakeven by end-2025 after annual net losses driven by SG\u0026amp;A: GAAP net loss was $85.4m in 2023 and $42.1m in 2024, with SG\u0026amp;A representing ~70% of operating expenses in 2024.\u003c\/p\u003e\n\u003cp\u003eThe market still treats Xeris as a transition-stage biotech; sustained net profitability and multi-quarter positive EBITDA are needed to attract conservative institutional investors and re-rate the stock.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eGAAP net loss: $85.4m (2023), $42.1m (2024)\u003c\/li\u003e\n\u003cli\u003eCash-flow breakeven reached Q4 2025\u003c\/li\u003e\n\u003cli\u003eSG\u0026amp;A ~70% of opex (2024)\u003c\/li\u003e\n\u003cli\u003eNeeds sustained profitability to de-risk for institutions\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLimited Global Commercial Infrastructure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eXeris generates about 85% of 2024 revenue from the United States, leaving Europe and Asia underpenetrated despite partnership attempts; direct commercial presence in major markets is minimal as of Dec 31, 2024.\u003c\/p\u003e\n\u003cp\u003eThis U.S. concentration raises exposure to domestic reimbursement or regulatory shifts and forfeits access to faster-growing diabetes and endocrine markets in China and EU (combined ~30% global market growth 2020–24).\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~85% revenue from U.S. (2024)\u003c\/li\u003e\n\u003cli\u003eNo major direct EU\/Asia sales force (2024)\u003c\/li\u003e\n\u003cli\u003eMissed ~30% regional market growth (2020–24)\u003c\/li\u003e\n\u003cli\u003eHigh policy\/regulatory concentration risk\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eXeris: High distributor\/PBM risk, narrow U.S. TAM, heavy SG\u0026amp;A \u0026amp; $160M debt\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHigh customer concentration (~45% of 2024 product sales tied to few distributors and two PBMs) and ~85% US revenue expose Xeris to rapid formulary\/reimbursement swings (12% quarterly sales swing in 2023). Niche portfolio limits TAM (Keveyis ~2–5k US patients; Recorlev ~20–30k), while heavy commercial SG\u0026amp;A (~$68M; ~70% of opex 2024) and ~$160M long-term debt cut FCF and slow profitability (GAAP losses $85.4M 2023; $42.1M 2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024 \/ note\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003e$226.6M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUS rev share\u003c\/td\u003e\n\u003ctd\u003e~85%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMajor distributor\/PBM share\u003c\/td\u003e\n\u003ctd\u003e~45%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLong-term debt\u003c\/td\u003e\n\u003ctd\u003e~$160M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSG\u0026amp;A\u003c\/td\u003e\n\u003ctd\u003e$68M (~70% opex)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGAAP net loss\u003c\/td\u003e\n\u003ctd\u003e$42.1M (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eKeveyis TAM\u003c\/td\u003e\n\u003ctd\u003e~2–5k US patients\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRecorlev TAM\u003c\/td\u003e\n\u003ctd\u003e~20–30k US patients\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eSame Document Delivered\u003c\/span\u003e\u003cbr\u003eXeris SWOT Analysis\u003c\/h2\u003e\n\u003cp\u003eThis is the actual SWOT analysis document you’ll receive upon purchase—no surprises, just professional quality.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56752514400633,"sku":"xerispharma-swot-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/xerispharma-swot-analysis.png?v=1772241903","url":"https:\/\/matrixbcg.com\/products\/xerispharma-swot-analysis","provider":"MatrixBCG","version":"1.0","type":"link"}